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Influenza epidemics occur during the winter
months in the Northern Hemisphere (October–
March)and cause approximately20 000deathsper
year in the US1. Influenza viruses cause disease
at all ages with infection rates highest among
children, especially those 0–6 months of age, and
serious illness and death rates highest among those
aged 65 years and over. Persons at any age who
have medical conditions that place them at high
risk for complications from influenza have
increased morbidity and mortality2.
Annual influenza vaccination is the primary
method for preventing influenza and its sequelae.
The primary target groups recommended for
annual vaccination include:
1) all persons aged 50 or over;
2) persons of any age who have chronic medical
conditions;
3) persons who live with or care for persons at
high risk, i.e. health care workers; and
4) all women who are pregnant during the
influenza season (October–March).
Vaccination is associated with a reduction in:
influenza-related respiratory illness and physician
visits among all age groups; hospitalization; death
among children with persistent high-risk otitis
media; and work absenteeism among adults3–5.
Epidemics of human influenza are caused by
two types: influenza A and influenza B. Influenza
A viruses are characterized into subtypes on the
basis of their two surface antigens: hemagglutinin
(H) and neuraminidase (N). InfluenzaB viruses are
not subtyped. Since 1977, Influenza A (H1N1)
viruses, Influenza A (H3N2) viruses, and Influenza
B viruses have been in worldwide circulation.
New variants arise due to point mutations that
occurduringviral replication(antigenic drift).The
development of antigenic variance through anti-
genic drift is the virologic basis for seasonal
epidemics and the reason for incorporation of
one or more new strains in each year’s vaccine.
The risk of serious complications, hospitaliza-
tionsandmortality frominfluenzais higheramong
persons aged 65 years and over, very young
children aged 0–6 months, and persons of any age
with high-risk medical conditions1. Rates of
influenza-associated hospitalizations have varied
substantially byage group(Table 1).Childrenaged
0–4 years have hospitalization rates approximately
500/100 000 population for those in high-risk
groups to 100/100 000 hospitalizations for those
without high-risk conditions. The information in
Table1 showsthe 0–11 month age groupwith the
low estimate for children age 6–11 months and the
high estimate for children aged 0–5 months. Few
studiesare available toassess theimpact ofmaternal
immunization with influenza vaccine in the neo-
nate. England and colleagues have championed
the concept of maternal immunization to protect
both the mother and neonate in months 0–6 of
life9,10. Since infants aged 0–6 months have a risk
of hospitalization as great as orgreater thanpersons
65 years of age or over, the only way to protect
pregnant women and their offspring is to adminis-
ter the vaccine in the second or third trimester of
pregnancy. Vaccination would be required during
pregnancy to allow for optimal antibody levels in
the infant.
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increased from 33% in 1989 to 63% in 1997 and
19983. Limited information is available regarding
the use of influenza vaccine in pregnant women.
Women aged 18–44 without diabetes reported in
1999 thatduringpregnancytheywere less likely to
receive an influenza vaccination than when not
pregnant (9.6% compared with 15.7%)3. This
indicateslowcompliancewithACIP’srecommen-
dations for pregnant women. In a subsequent
study11, influenza vaccine acceptance by pregnant
women occurred in 71% of those who were
offered the vaccine. Gonik and colleagues12 sur-
veyed obstetrician gynecologists in Michigan and
determined that only 39% gave influenza vaccine
to obstetricspatients,but86%agreed thatpregnant
women’s risk for influenza-related morbidity and
mortality increased in the second and third tri-
mesters of pregnancy. Targeted groups for vacci-
nation include:
1) all persons aged 50 years and over;
2) women who will be pregnant during the
influenza season;
3) residents of nursing homes and chronic care
facilities of any age;
4) adults and children who have chronic disor-
ders of the pulmonary or cardiovascular sys-
tems including asthma and smoking;
5) adults and children who require regular
medical examination or who have been
hospitalized in the last year because of dia-
betes mellitus, renal or hemalologic disease,
or immunosuppression; and
6) health care providers.
The impact of influenza during pregnancy can be
devastating. Influenza-associated excess deaths
were seen in the pandemics of 1918–19 and
1957–5813. Case-facility ratio reached 60% in the
1918–19 pandemic. Alterations of pregnancy
physiologyaredetrimentalto,andincreaseseverity
of,alltypesofpneumoniasinpregnancy.Thereare
increases in heart rate, stroke volume and oxygen
consumption, decreases in lung capacity, and
changes in immunologic function14. Neuzil and
colleaguesreportedontheimpactofinfluenzadur-
ing 17 interpandemic influenza seasons, and found
the relative risk for hospitalization with
cardiorespiratory conditions increased from 1.4
during weeks 14–20 of pregnancy to 4.7 during
weeks 37–42, compared with women who were
1–6 months postpartum15.
The current trivalent vaccine is an inactivated
vaccine and is considered safe in all trimesters of
pregnancy. A study of influenza vaccination
of over 2000 pregnant women16 demonstrated no
adverse fetal effects associated with the vaccine.
Influenza vaccine administration in the first tri-
mester, while safe, may occur with a coincidental
spontaneousabortion and consideration should be
given to defer vaccine until the second trimester.
Influenza vaccine does not affect the safety of
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Study years Age group
Hospitalizations/100,000
persons at high risk
Hospitalizations/100,000
persons not at high risk
1973–19936
1992–19977
1968–19698
1968–19958
0–11 m
1–2 y
3–4 y
5–14 y
0–23 m
2–4 y
5–17 y
15–44 y
45–64 y
‡ 65 y
< 65 y
‡ 65 y
1900
800
320
92
56–110
392–635
399–518
496–1038
186
86
41
144–187
0–25
8–12
23–25
13–23
—
20–42
125–228
Table 1 Estimated rates of influenza-associated hospitalization by age groupmothers who are breastfeeding, or their infants –
breastfeeding is not a contraindication for
vaccination.
Influenza vaccinations should be administered
during the months of October–March. Table 2
shows the month of peak influenza activity during
19 influenza seasons in the US. The implication is
that the influenza season is not over by November
but pregnant women should be vaccinated up to
and including March.
Influenza vaccine should be given intramuscu-
larly (IM) with a needle ‡ 1 inch in the deltoid
muscle. Inactivated vaccine should notbe given to
persons who have anaphylactic hypersensitivity
to eggs or to other components of the influenza
vaccine.
Influenza can cause serious complications and
mortality. Pregnant women of all ages are a tar-
getedgroupasareallpeopleaged50orover.Influ-
enza vaccine reduces significant morbidity and
there is preliminary data suggesting a reduction of
influenza and otitis media in infants aged 0–6
months.
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December January February March
Number of years with peak influenza activity 4 (21%) 5 (26%) 7 (37%) 3 (16%)
Table 2 Month of peak influenza activity during 19 influenza seasons
3
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